Toxicity and Pharmacokinetic Studies of Aerosolized Clinical Grade Azacitidine

Aerosol Aza aerodynamic size favors deposition of the drug to the human lower airways. The aerosol process do not compromise the drug activity. Aerosolized Aza has higher lung deposition and much less systemic toxicity than IV drug. The safe starting dose for clinical phase I trials should be 2.5 mg/m2 for 5 to 7 days.